Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-Sparing Daratumumab and Lenalidomide in Newly Diagnosed Multiple Myeloma
NCT04635189Phase 2Active, not recruiting
- Sponsor
- University of Rochester
- Start
- Jul 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab, lenalidomide in multiple myeloma (MM), sponsored by University of Rochester. Started Jul 2021; status: active, not recruiting.
02
Drugs
daratumumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04635189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635189.